Ubs Group Ag Moon Lake Immunotherapeutics Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Ubs Group Ag holds 27,918 shares of MLTX stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,918

Previous 6,340 340.35%

Holding current value

$1.11 Million

Previous $319,000 364.89%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$45.84 - $57.91 $989,135 - $1.25 Million	21,578 Added 340.35%	27,918 $1.48 Million
Q3 2024 Nov 14, 2024	BUY	$40.15 - $55.4 $123,380 - $170,244	3,073 Added 94.06%	6,340 $319,000
Q2 2024 Aug 13, 2024	SELL	$38.43 - $48.6 $441,368 - $558,171	-11,485 Reduced 77.85%	3,267 $143,000
Q1 2024 May 13, 2024	BUY	$43.78 - $63.86 $617,779 - $901,128	14,111 Added 2201.4%	14,752 $740,000
Q4 2023 Feb 09, 2024	SELL	$36.35 - $63.02 $17,593 - $30,501	-484 Reduced 43.02%	641 $38,000
Q3 2023 Nov 09, 2023	BUY	$48.35 - $61.26 $54,393 - $68,917	1,125 New	1,125 $64,000
Q1 2023 May 12, 2023	SELL	$11.03 - $23.7 $721,670 - $1.55 Million	-65,428 Reduced 89.15%	7,960 $170,000
Q4 2022 Feb 08, 2023	SELL	$7.05 - $10.5 $16,045 - $23,898	-2,276 Reduced 3.01%	73,388 $770,000
Q3 2022 Nov 10, 2022	BUY	$5.25 - $9.27 $10,521 - $18,577	2,004 Added 2.72%	75,664 $587,000
Q2 2022 Aug 10, 2022	BUY	$4.69 - $13.25 $345,465 - $975,995	73,660 New	73,660 $387,000

Others Institutions Holding MLTX

# of Institutions

137

Shares Held

58.1M

Call Options Held

124K

Put Options Held

96.9K

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.46B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account